Recent events
Recent events tied to this brand in public sources.
Back to profile30 entries · Page 1 of 2
2026
Eli Lilly raises its 2026 revenue outlook
Eli Lilly raised its expected 2026 revenue range to $91 billion–$92 billion, from its previous guidance of $85 billion–$87 billion.
2026
METiS TechBio and Eli Lilly announce drug-delivery partnership
METiS TechBio and Eli Lilly announced a partnership to develop lipid nanoparticle-based delivery solutions, combining METiS's AI-driven lipid design with Lilly's drug discovery, development, and commercialization expertise. The deal is worth up to approximately $1.1 billion in potential milestone payments, in addition to an upfront payment and potential royalties.
2026
Eli Lilly weight-loss pill receives EU regulator backing
Reuters reports that Eli Lilly's weight-loss pill received backing from an EU drug regulator; the headline does not specify the date or details of the backing.
2026
Patient sues Eli Lilly over stomach problems tied to Mounjaro and Trulicity
A patient has filed a lawsuit against Eli Lilly, alleging stomach problems that the patient ties to the medications Mounjaro and Trulicity, as reported by The Indiana Lawyer.
2026
Eli Lilly reports Phase 2 results showing eloralintide plus tirzepatide produced substantially more weight loss
Eli Lilly reported Phase 2 trial data showing that its experimental amylin-targeting drug eloralintide, when combined with tirzepatide (the active ingredient in its Zepbound and Mounjaro shots), produced substantially more weight loss in patients with obesity and Type 2 diabetes. At 48 weeks, the highest-dose combination group lost an average of 23.3% of body weight versus 14.8% on a high dose of tirzepatide alone. More patients on the combination discontinued treatment due to side effects (10.8% to 27% depending on dose) than on tirzepatide alone (2.9%), and Lilly needs to confirm the results in Phase 3 trials that will begin later this year.
2026
Eli Lilly breaks ground on $6.5 billion Houston manufacturing facility to ramp up Foundayo production
Eli Lilly broke ground on its planned $6.5 billion manufacturing facility at Generation Park in Houston, Texas, which the company expects to be operational by 2030 and which will produce ingredients for the Foundayo obesity pill and other small-molecule medicines.
2026
Eli Lilly launches oral weight-loss drug Foundayo in the UK
Eli Lilly launched its oral weight-management and type 2 diabetes drug Foundayo (orforglipron) in the UK via private prescription, making Britain the first country in Europe where the oral treatment is available. The drug was authorised by Britain's medicines regulator on August 10, and Lilly said it is working with NICE during the agency's assessment for weight management access.
2026
Eli Lilly files lawsuits against six companies over alleged illegal retatrutide sales
Eli Lilly filed six lawsuits against Aesthetic Envy Cosmetic Centers, Astra, Legendary Peptides, Striker Pharmacy, Texas Peptides and Lone Star Peptide, alleging they sell counterfeit, unapproved versions of its investigational diabetes and obesity drug retatrutide, which is not yet FDA approved.
2022
Eli Lilly announces an approximately $700 million facility investment
Eli Lilly revealed plans for an investment of around $700 million to establish a facility at its new site in Boston, as part of its plan to advance RNA-based treatments.
2021
Eli Lilly announces a planned 40% insulin price reduction
Eli Lilly announced that it would lower the price of the insulin it produces by 40%, starting January 1, 2022. The article reports an announced future price change, not that the reduction had already taken effect.
2021
FDA approves Lyumjev for insulin-pump use
The US Food and Drug Administration expanded the label for Eli Lilly's Lyumjev, approving the 100 units/mL formulation for delivery through an insulin pump.
2021
Eli Lilly and MiNA Therapeutics enter research collaboration
Eli Lilly and MiNA Therapeutics entered a global research collaboration to develop therapies using MiNA’s small activating RNA technology platform. MiNA will apply the platform to up to five targets selected by Lilly.
2021
Former lobbyist sues Eli Lilly over alleged workplace discrimination and harassment
Former Eli Lilly lobbyist Sonya Elling filed a lawsuit alleging that company executives discriminated against and harassed women and retaliated against her. Eli Lilly was the only named defendant; a Lilly spokeswoman denied the allegations.
2021
Eli Lilly and Biolojic enter diabetes antibody therapy collaboration
Eli Lilly and Biolojic entered into an agreement under which Eli Lilly can use Biolojic's AI-based multi-antibody platform to discover and develop antibody-based diabetes treatments. The reported deal value was $121 million.
2021
Eli Lilly appoints Anat Ashkenazi CFO
Eli Lilly said Anat Ashkenazi will step into the role of senior vice president and chief financial officer.
2021
Eli Lilly CFO Josh Smiley resigns
Eli Lilly announced that CFO Josh Smiley resigned with immediate effect following a company probe that found inappropriate personal communications with multiple employees. The company said the conduct was not related to financial controls or business matters.
2021
Eli Lilly partners to establish Indiana COVID-19 infusion centers
Eli Lilly partnered with the state of Indiana and health systems to establish three infusion centers providing its COVID-19 antibody therapy.
2020
Eli Lilly announced an agreement to acquire Prevail Therapeutics
Eli Lilly announced it would acquire Prevail Therapeutics for about $1 billion. Under the agreement, Prevail shareholders would receive $22.50 per share, including a contingent value right tied to regulatory approval of a product in development.
2020
FDA authorizes Eli Lilly coronavirus antibody therapy for emergency use
The FDA granted emergency use authorization to a coronavirus antibody therapy made by Eli Lilly for people with mild to moderate symptoms who are at risk of more serious illness.
2020
Boryung acquires Korean rights to Gemzar
Boryung Pharmaceutical acquired all rights to Eli Lilly’s anti-cancer drug Gemzar in South Korea.